Myron G. Hill

Array ( [id] => 19311560 [patent_doc_number] => 12037363 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Peptides for Covid-19 prevention and treatment [patent_app_type] => utility [patent_app_number] => 17/393328 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 22 [patent_no_of_words] => 22024 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597211 [patent_doc_number] => 20230272005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => Amino Acid Sequence Derived from Sars-Cov-2 and Use Thereof [patent_app_type] => utility [patent_app_number] => 18/007092 [patent_app_country] => US [patent_app_date] => 2021-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18523007 [patent_doc_number] => 20230233661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => VACCINE COMBINATION AGAINST REPIRATORY SYNCYTIAL VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/003547 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332603 [patent_doc_number] => 20240247033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => SARS-COV-2 RBD CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 18/002611 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18071632 [patent_doc_number] => 11530457 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Saliva-based molecular testing for SARS-CoV-2 [patent_app_type] => utility [patent_app_number] => 17/636469 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 15 [patent_no_of_words] => 15612 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18565749 [patent_doc_number] => 20230256076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => RSV VACCINE COMPOSITIONS, METHODS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/009150 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612630 [patent_doc_number] => 20230279362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS [patent_app_type] => utility [patent_app_number] => 18/008393 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548113 [patent_doc_number] => 20220119454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS [patent_app_type] => utility [patent_app_number] => 17/332901 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24881 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955177 [patent_doc_number] => 20240043504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments [patent_app_type] => utility [patent_app_number] => 17/927649 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20881365 [patent_doc_number] => 12697384 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-04 [patent_title] => Multiple antigenic peptide against corona virus and immunostimulating composition containing the same [patent_app_type] => utility [patent_app_number] => 17/926975 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 32 [patent_no_of_words] => 11238 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18452032 [patent_doc_number] => 20230193311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => IMMUNOGENIC COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/925966 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597220 [patent_doc_number] => 20230272014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => COMPOSITION OF NANOPARTICLES AS CARRIER FOR HPV-DERIVED IMMUNOGENIC FRAGMENTS [patent_app_type] => utility [patent_app_number] => 17/924193 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067274 [patent_doc_number] => 20210269489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => PRE-FUSION RSV F ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/314649 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 174272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420126 [patent_doc_number] => 20230174587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 17/919733 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17183837 [patent_doc_number] => 20210330722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION [patent_app_type] => utility [patent_app_number] => 17/241957 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18361624 [patent_doc_number] => 20230143215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => IMMUNIZATION AGAINST SARS-COV-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/920416 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673106 [patent_doc_number] => 20230310582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => SARS-2 SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE [patent_app_type] => utility [patent_app_number] => 17/919111 [patent_app_country] => US [patent_app_date] => 2021-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213154 [patent_doc_number] => 20210346490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/226690 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17110160 [patent_doc_number] => 20210290757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => ENGINEERING OF DENDRITIC CELLS FOR GENERATION OF VACCINES AGAINST SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 17/210409 [patent_app_country] => US [patent_app_date] => 2021-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17210409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19218286 [patent_doc_number] => 20240182990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => DETECTION OF INFECTIOUS AGENT BASED ON RECOMBINASE POLYMERASE AMPLIFICATION COMBINED WITH A MAGNETIC FIELD-ENHANCED AGGLUTINATION [patent_app_type] => utility [patent_app_number] => 18/549058 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549058 [rel_patent_id] =>[rel_patent_doc_number] =>)